Sara Pusceddu

List of Publications by Citations

71 papers	1,119 citations	18 h-index	30 g-index
75 ext. papers	1,406 ext. citations	4 avg, IF	3.9 L-index

#	Paper	IF	Citations
71	The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. *Neuroendocrinology*, **2017**, 104, 85-93	5.6	137
70	Real-world study of everolimus in advanced progressive neuroendocrine tumors. *Oncologist*, **2014**, 19, 966-74	5.7	66
69	A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer. *Critical Reviews in Oncology/Hematology*, **2012**, 81, 185-95	7	56
68	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. *Cancer*, **2014**, 120, 2457-63	6.4	52
67	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. *Cancer Treatment Reviews*, **2019**, 72, 45-55	14.4	51
66	Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. *Cancers*, **2019**, 11,	6.6	45
65	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. *Annals of Oncology*, **2014**, 25, 1597-603	10.3	45
64	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. *Endocrine*, **2018**, 60, 490-498	4	41
63	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology*, **2018**, 155, 479-489.e7	13.3	36
62	Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. *European Journal of Surgical Oncology*, **2017**, 43, 380-387	3.6	35
61	Treatment of lung large cell neuroendocrine carcinoma. *Tumor Biology*, **2016**, 37, 7047-57	2.9	34
60	Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. *Annals of Oncology*, **2007**, 18, 1810-6	10.3	28
59	Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. *Oncology*, **2007**, 73, 204-9	3.6	27
58	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. *Critical Reviews in Oncology/Hematology*, **2018**, 123, 57-73	7	26
57	Diagnosis and management of typical and atypical lung carcinoids. *Critical Reviews in Oncology/Hematology*, **2016**, 100, 167-76	7	26
56	Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis. *Radiotherapy and Oncology*, **2019**, 134, 211-219	5.3	24
55	Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. *Neuroendocrinology*, **2020**, 110, 616-629	5.6	22

54	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. *Future Oncology*, **2016**, 12, 1251-60	3.6	19
53	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. *Therapeutic Advances in Medical Oncology*, **2017**, 9, 183-188	5.4	17
52	Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report. *International Journal of Gynecological Pathology*, **2008**, 27, 596-600	3.2	17
51	Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms. *Journal of Pathology: Clinical Research*, **2019**, 5, 217-226	5.3	16
50	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. *Pancreatology*, **2018**, 18, 198-203	3.8	14
49	Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?. *Tumori*, **2011**, 97, 564-7	1.7	14
48	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	14
47	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocrine-Related Cancer*, **2018**, 25, 607-618	5.7	13
46	Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update. *Neuroendocrinology*, **2018**, 106, 307-311	5.6	13
45	Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. *Tumori*, **2014**, 100, e286-9	1.7	13
44	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. *Tumor Biology*, **2016**, 37, 12991-13003	2.9	12
43	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. *Clinical Colorectal Cancer*, **2020**, 19, 156-164	3.8	12
42	The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. *Tumori*, **2018**, 104, 88-95	1.7	11
41	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. *Targeted Oncology*, **2018**, 13, 567-582	5	11
40	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. *Cancer Medicine*, **2017**, 6, 1493-1499	4.8	9
39	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. *Future Oncology*, **2015**, 11, 1947-59	3.6	9
38	The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. *Targeted Oncology*, **2018**, 13, 333-351	5	9
37	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. *Oncotarget*, **2016**, 7, 44841-44847	3.3	9

36	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). *International Journal of Cancer*, **2019**, 144, 1704-1712	7.5	9
35	Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. *Neuroendocrinology*, **2021**, 111, 475-489	5.6	9
34	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. *Journal of Cancer Research and Clinical Oncology*, **2017**, 143, 1209-1224	4.9	8
33	Safety profile and treatment response of everolimus in different solid tumors: an observational study. *Future Oncology*, **2014**, 10, 1611-7	3.6	8
32	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. *Pancreatology*, **2019**, 19, 1067-1073	3.8	7
31	Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. *Targeted Oncology*, **2011**, 6, 181-6	5	7
30	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. *Endocrine*, **2017**, 57, 512-517	4	6
29	Article Commentary: Everolimus in Advanced Solid Tumors: When to Start, Early or Late?. *Tumori*, **2014**, 100, e2-e3	1.7	6
28	Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
27	Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. *Frontiers in Oncology*, **2019**, 9, 902	5.3	5
26	Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups. *Cancers*, **2020**, 12,	6.6	5
25	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. *Future Oncology*, **2017**, 13, 1677-1683	3.6	4
24	Update on medical treatment of small intestinal neuroendocrine tumors. *Expert Review of Anticancer Therapy*, **2016**, 16, 969-76	3.5	4
23	Sunitinib and Everolimus in Pancreatic Neuroendocrine Tumors. *Tumori*, **2012**, 98, 394-394	1.7	4
22	Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum. *Cancers*, **2012**, 4, 808-20	6.6	4
21	Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. *Tumori*, **2013**, 99, e148-51	1.7	4
20	Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. *Tumori*, **2019**, 105, 113-120	1.7	4
19	Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes. *Tumori*, **2009**, 95, 501-507	1.7	3

18	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. *Oncology Reviews*, **2009**, 3, 79-87	4.3	3
17	Everolimus in advanced solid tumors: when to start, early or late?. *Tumori*, **2014**, 100, e2-3	1.7	3
16	Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature. *Oncology Research*, **2011**, 19, 403-6	4.8	3
15	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284820927271	4.7	3
14	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. *Clinical Lung Cancer*, **2021**, 22, 161-169	4.9	3
13	Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?. *Annals of Oncology*, **2013**, 24, 1415-6	10.3	2
12	Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.. *Journal of Clinical Oncology*, **2013**, 31, 4136-4136	2.2	2
11	Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
10	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. *Case Reports in Oncology*, **2016**, 9, 432-439	1	2
9	Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm. *Scandinavian Journal of Gastroenterology*, **2019**, 54, 1111-1117	2.4	1
8	Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. *International Journal of Colorectal Disease*, **2015**, 30, 429-30	3	1
7	Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?. *Oncologist*, **2020**, 25, e1257-e1258	5.7	1
6	Everolimus treatment in advanced solid tumors: a personal view. *Future Science OA*, **2015**, 1, FSO3	2.7	1
5	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.. *Frontiers in Oncology*, **2022**, 12, 780716	5.3	1
4	Update on Therapeutic Strategy in Lung Carcinoids. *Journal of Cancer Therapy*, **2013**, 04, 1466-1471	0.2	1
3	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. *Future Oncology*, **2019**, 15, 3015-3024	3.6	0
2	Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma. *Frontiers in Oncology*, **2021**, 11, 628324	5.3	0
1	NETs of the Lung **2021**, 163-178		0